Australia's Integral Diagnostics gains; Jefferies upbeat on FY26 EBITDA outlook

Integral Diagnostics

08/04/2025 02:33

Adds share move and milestone, updates YTD move in bullet 1 and 7, respectively

** Integral Diagnostics IDX.AX gains 0.9% to A$2.16; marks biggest intraday percentage gain since March 27

** Jefferies says several factors can potentially lead to upside for co's FY26 EBITDA estimates

** Adds potential factors include upgrading from partial to full MRI Licences, which could drive MRI volumes and lung cancer screening

** Maintains PT at A$3.60, retains "buy"

** Says IDX has 16 partial licences that will be upgraded, which should drive MRI volume and increase co's market share of MRIs by 183bp to 10.3%

** Stock rated "buy" on avg; median PT is A$3.10, per data compiled by LSEG

** IDX down ~26% this year, as of last close

 (Reporting by Shivangi Lahiri in Bengaluru)

 ((shivangi.lahiri@thomsonreuters.com))